A novel liposome radiolabeling method using 99mTc-" SNS/S" complexes: In vitro and in vivo evaluation

Journal of Pharmaceutical Sciences

Volumn 92, Issue 9, 2003, Pages 1893-1904

  Bao, Ande ^a   Goins, Beth ^a   Klipper, Robert ^a   Negrete, George ^b   Mahindaratne, Mathew ^b   Phillips, William T ^a  

^a Mays Cancer Center at UT Health San Antonio   (United States)

^b UNIVERSITY OF TEXAS AT SAN ANTONIO   (United States)

Author keywords

"SNS S" complexes; Liposomes; Radiolabeling; Stability; Technetium 99m

Indexed keywords

BUTYLAMINE; CHOLESTEROL; DISTEAROYLPHOSPHATIDYLCHOLINE; DRUG CARRIER; GLUTATHIONE; LIGAND; LIPOSOME; N,N BIS(2 MERCAPTOETHYL) 1 BUTYLAMINE; N,N BIS(2 MERCAPTOETHYL) N',N'' DIETHYLETHYLENEDIAMINE; RHENIUM; RHENIUM 186; RHENIUM 188; TECHNETIUM 99M; TECHNETIUM 99M SNS S COMPLEX; THIOL DERIVATIVE; THIOPHENOL; UNCLASSIFIED DRUG;

ANALYTIC METHOD; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BLOOD ANALYSIS; CALCULATION; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DNA DRUG COMPLEX; DOSE TIME EFFECT RELATION; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG POTENCY; DRUG STABILITY; EVALUATION; GENE THERAPY; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; NONHUMAN; RADIOISOTOPE DIAGNOSIS; RAT; SPLEEN; SPLEEN CELL;

EID: 0041336621     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1002/jps.10441     Document Type: Article

References (48)

1. Dass CR, Burton MA. 1999. Lipoplexes and tumours: A review. J Pharm Pharmacol 51:755-770.
2. Drummond DC, Meyer O, Hong K, Kirpotin DB, Papahadjoupolos D. 1999. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev 51:691-743.
3. Lasic DD. 1997. Liposomes in gene therapy. Boca Raton, FL: CRC Press.
4. Harris JD, Lemoine NR. 1996. Strategies for targeted gene therapy. Trends Genet 12:400-405.
5. 99mTc-antisense oligonucleotides in target tumor cells. Cancer Biother Radiopharm 16:411-419.
6. Gregoriadis G, Garcon N, da Silva H, Sternberg B. 1993. Coupling of ligands to liposomes independently of solute entrapment: Observations on the formed vesicles. Biochim Biophys Acta 1147: 185-193.
7. Green S, Fortier A, Dijkstra J, Madsen J, Swartz G, Einck L, Gubish E, Nacy C. 1995. Liposomal vaccines. Adv Exp Med Biol 383:83-92.
8. Owais M, Masood AK, Agrewala JN, Bisht D, Gupta CM. 2001. Use of liposomes as an immunopotentiating delivery system: In perspective of vaccine development. Scand J Immunol 54:125-132.
9. Goins BA, Phillips WT. 2001. The use of scintigraphic imaging as a tool in the development of liposome formulations. Prog Lipid Res 40(1-2): 95-123.
10. 99mTc-technetium-labelled liposomes. J Med Microbiol 14:213-217.
11. Goins B, Klipper R, Rudolph AS, Cliff RO, Blumhardt R, Phillips WT. 1993. Biodistribution and imaging studies of technetium-99m-labeled liposomes in rats with focal infection. J Nucl Med 34:2160-2168.
12. Oyen WJ, Boerman OC, Storm G, van Bloois L, Koenders EB, Claessens RA, Perenboom RM, Crommelin DJ, van der Meer JW, Corstens FH. 1996. Detecting infection and inflammation with technetium-99m-labeled Stealth liposomes. J Nucl Med 37:1392-1397.
13. Boerman OC, Oyen WJ, van Bloois L, Koenders EB, van der Meer JW, Corstens FH, Storm G. 1997. Optimization of technetium-99m-labeled PEG liposomes to image focal infection: Effects of particle size and circulation time. J Nucl Med 38:489-493.
14. Awasthi V, Goins B, Klipper R, Loredo R, Korvick D, Phillips WT. 1998. Imaging experimental osteomyelitis using radiolabeled liposomes. J Nucl Med 39:1089-1094.
15. 99mTc-biotin-PEG liposomes. J Nucl Med 41:912-918.
16. Harrington KJ, Rowlinson-Busza G, Syrigos N, Uster PS, Vile RG, Stewart JSW. 2000. Pegylated liposomes have potential as vehicles for intratumoral and subcutaneous drug delivery. Clinic Cancer Res 6:2528-2537.
17. Emfietzoglou D, Kostarelos K, Sgouros G. 2001. An analytic dosimetry study for the use of radionuclide-liposome conjugates in internal radiotherapy. J Nucl Med 42:499-504.
18. 99mTc-labelled liposomes preparation of radiopharmaceutical and its distribution in a hepatoma patient. Int J Nucl Med Biol 5:121-122.
19. Hnatowich DJ, Friedman B, Clancy B, Novak M. 1981. Labeling of preformed liposomes with Ga-67 and Tc-99m by chelation. J Nucl Med 22:810-814.
20. Phillips WT, Rudolph AS, Goins B, Timmons JH, Klipper R, Blumhardt R. 1992. A simple method for producing a technecium-99m-labeled liposome, which is stable in vivo. Nucl Med Biol 19:539-547.
21. Oku N, Namba Y, Takeda A, Okada S. 1993. Tumor imaging with technetium-99m-DTPA encapsulated in RES-avoiding liposomes. Nucl Med Biol 20:407-412.
22. 99mTc-labeling of lipid vesicles containing the lipophilic chelator PE-DTTA: Effect of tin-to-chelate ratio, chelate content and surface polymer on labeling efficiency and biodistribution behavior. Nucl Med Biol 21:89-96.
23. 99mTc-labelled diphytanoylphosphatidylcholine liposomes: In vitro and in vivo studies. J Microencapsul 14:427-436.
24. 99mTc by the hydrazino nicotinyl derivative. J Nucl Med 40:192-197.
25. 67Gallium-labeled liposomes with prolonged circulation: Preparation and potential as nuclear imaging agents. Nucl Med Biol 20:149-155.
26. 111In-tagged liposomes. Nucl Med Biol 14:33-35.
27. 3+-bound inulin. Biochim Biophys Acta 944:329-336.
28. Oku N. 1999. Delivery of contrast agents for positron emission tomography imaging by liposomes. Adv Drug Del Rev 37:53-61.
29. Mastrostamatis SG, Papadopoulos MS, Pirmettis IC, Paschali E, Varvarigou AD, Stassinopoulou CI, Raptopoulou CP, Terzis A, Chiotellis E. 1994. Tridentate ligands containing the SNS donar atom set as a novel backbone or the development of technetium brain-imaging agents. J Med Chem 37: 3212-3218.
30. Pelecanou M, Pirmettis IC, Papadopoulos MS, Terzis A, Chiotellis E, Stassinopoulou CI. 1999. Structural studies of ReO(V) mixed ligand [SNS][Cl] and [SNS][S] complexes. Inorg Chim Acta 287:142-151.
31. 188Re-liposome radiolabeling for nuclear imaging and targeted radionuclide therapy. In: Nicolini M, Mazzi U, editors. Technetium, rhenium and other metals in chemistry and nuclear medicine, 6. Padova, Italy: SGE, pp 381-386.
32. 2+ core. Inorg Chim Acta 90:41-51.
33. Goins B, Phillips WT, Klipper R. 1996. Blood-pool imaging using technetium-99m-labeled liposomes. J Nucl Med 37:1374-1379.
34. Stewart JCM. 1980. Colorimetric determination of phospholipids with ammonium ferrothiocyanate. Anal Biochem 104:10-14.
35. Petty C. 1982. Research techniques in the rat. Springfield, IL: Charles C. Thomas, pp 66-70.
36. Frank DW. 1976. Physiological data of laboratory animals. In: Melby EC Jr, Altman NH, editors. Handbook of laboratory animal science, volume III. Boca Raton, FL: CRC Press, pp 23-64.
37. 188Re incorporated in liposomes suitable for radiotherapy. Nucl Med Biol 18:449-454.
38. Tilcock C. 1999. Delivery of contrast agents for magnetic resonance imaging, computed tomography, nuclear medicine and ultrasound. Adv Drug Del Rev 37:33-51.
39. Deutsch E, Libson K, Vanderheyden J-L, Ketring AR, Maxon HR. 1986. The chemistry of rhenium and technecium as related to the use of isotopes of these elements in therapeutic and diagnostic nuclear medicine. Nucl Med Biol 13:465-477.
40. Yoshihara K, Omori T, (editors). 1996. Technetium and rhenium, their chemistry and its applications (Topics in Current Chemistry 176). Springer: Heidelberg, Germany.
41. Hung JC, Corlija M, Volkert WA, Holmes RA. 1988. Kinetic analysis of technetium-99m d,l-HMPAO decomposition in aqueous media. J Nucl Med 29:1568-1576.
42. Spies H, Pietzsch HJ, Syhre R, Hoffmann S. 1990. Lipophilic technecium complexes-VIII: Preparation and animal studies of oxotechnetium(V) complexes with tridentate/monodentate ligand coordination. Isotopenpraxis 26:159-162.
43. Pirmettis IC, Papadopoulos MS, Mastrostamatis CP, Raptopoulou CP, Terzis A, Chiotellis E. 1996. Synthesis and characterization of oxotechnetium(V) mixed-ligand complexes containing a tridentate N-substituted bis(2-mercaptoethyl) amine and a monodentate thiol. Inorg Chem 35:1685-1691.
44. Nock BA, Maina T, Yannoukakos D, Pirmettis IC, Papadopoulos MS, Chiotellis E. 1999. Glutathione-mediated metabolism of technetium-99m SNS/S mixed ligand complexes: A proposed mechanism of brain retention. J Med Chem 42:1066-1075.
45. Weber DA, Eckerman KF, Dillman LT, Ryman JC. 1989. MIRD: Radionuclide data and decay schemes. Society of Nuclear Medicine. New York, NY.
46. Wagner HN Jr. 2002. Highlights 2002 lecture: Reinventing clinical nuclear medicine. J Nucl Med 43(8):11N-39N.
47. Matteucci ML, Anyaramdhatla G, Rosner G, Azuma C, Fisher PE, Dewhirst MW, Needham D, Thrall DE. 2000. Hyperthermia increases accumulation of technetium-99m-labeled liposomes in feline sarcomas. Clin Cancer Res 6:3748-3755.
48. Koukourakis MI, Koukouraki S, Giatromanolaki A, Kakolyris S, Georgoulias V, Velidaki A, Archimandritis S, Karkavitsas NN. 2000. High intratumoral accumulation of stealth liposomal doxorubicin in sarcomas-Rationale for combination with radiotherapy. Acta Oncol 39:207-211.